By adding our Bluetooth enabled meter to its lineup, Glooko is able to leverage seamless access to blood glucose data in order to deliver actionable information that is accessible near real time.
Palo Alto, California (PRWEB) September 24, 2015
Glooko Inc., the leading unified platform for diabetes management, today announced general availability of its integration with Roche’s Accu-Chek Aviva Connect blood glucose meters to send blood glucose (BG) results automatically to the Glooko platform. Through wireless Bluetooth Smart technology built into these Accu-Chek Aviva Connect meters, the release enables near real-time syncing of blood glucose data to the Glooko platform without the need to connect cables. Data syncing happens in the background directly after blood glucose readings are measured by people using an Accu-Chek Aviva Connect meter.
With this latest integration, Glooko addresses a long-standing deterrent to tracking blood glucose trends: manual entry and syncing of blood glucose data into apps and disease management systems to help patients and clinicians better manage diabetes. When people with diabetes use a Bluetooth enabled Accu-Chek Aviva Connect meter, they simply have to check their blood glucose and their data becomes automatically available in Glooko, where it is combined with exercise, diet, CGM, pump and medication data in a series of reports and analytics.
Traditional mobile health solutions that require manual entry of BG data have struggled to capture accurate data and keep users engaged, resulting in missing data points and an inability to review accurate glucose trends necessary for diabetes decision making. With its support for Accu-Chek Aviva Connect meters, Glooko builds on its device-agnostic platform, which is focused on making diabetes management easier through data accessibility and advanced analytics.
“We are excited that Glooko has chosen to add the Accu-Chek Aviva Connect meter to its platform,” said Laura Spiegel, Group Marketing Manager of Strategy and Innovation at Roche Diagnostics Corporation. “By adding our Bluetooth enabled meter to its lineup, Glooko is able to leverage seamless access to blood glucose data in order to deliver actionable information that is accessible near real time. Individuals using Accu-Chek Aviva Connect can easily share this information with their care team to support better decisions and care adjustments for positive health outcomes.”
With this new integration to the Glooko platform, a patient’s family members and their care team can use the Glooko mobile and web apps to remotely monitor their blood glucose as well as other important information, such as insulin, carb and fitness data in a single platform. The patient’s care team can also access this information and connect with patients who require more attention. “In situations where a patient is experiencing dangerous hypoglycemic events, Roche’s seamless transfer of blood glucose data through Glooko in near real time to the smartphone triggers Glooko to engage patients in creating better hypoglycemic awareness via the Joslin HypoMap™ survey and other pattern recognition features, giving patients and their care teams the ability to actively mitigate these issues,” said Michelle de Haaff, Glooko’s Vice President of Marketing.
To learn more about what blood glucose, pump, CGM, exercise and mobile devices that Glooko integrates with, visit our website compatibility page.
The Accu-Chek Aviva Connect meter can found exclusively at Walgreens nationwide.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For 40 years, the Accu-Chek brand has been dedicated to enable people with diabetes to live life as normal and active as possible as well as to empower healthcare professionals manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome. For more information: http://www.accu-chek.com.
All trademarks used or mentioned in this release are legally protected.
Glooko is the Unified Platform for Diabetes Management and provides an FDAcleared, HIPAAcompliant Web and Mobile application for diabetes patients and clinicians, which aims to improve outcomes and lowers costs. The platform seamlessly unifies data from over 50 leading blood glucose meters, insulin pumps, continuous glucose monitors, activity trackers and biometric devices to deliver insights that improve personal and clinical decision support. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offers diabetes centric analytics and supplies insightful reports, graphs and patterntriggered notifications to patients, health systems and payers. The Glooko platform also allows customers and third party developers to create branded modules for Glooko users. Learn more at http://www.glooko.com and follow us at Twitter.com/GlookoInc, and Facebook.com/Glooko.